MIP Technologies Raises Capital

MIP Technologies AB has announced the completion of another round of financing totalling USD 4 million. Catella Healthcare Investments AB, a new investor, was responsible for the majority of the investment. Other investments were made by Malmöhus Invest and the company management.

The new funds will ensure further expansion of the product offering, and the forming of new strategic alliances with large companies with a growing need for innovative solutions in the separation area.

MIP Technologies AB is a leading company in the development of molecularly imprinted polymers, MIPs. MIPs are stable polymer materials in which artificial receptor sites have been created for use in separations and drug discovery. The company is dedicated to the development and marketing of innovative, MIP-based products, directly and through collaborations. MIPs are 'selective separation phases' and as such can be applied in analytical sample pre-treatment, chemical sensing, dedicated separations or as screening elements in drug discovery. Currently the company has alliances in place with three blue chip companies. MIP Technologies has worked with the Center for Disease Control in Atlanta and is currently under contract with the US Environmental Protection Agency.

For further information please contact:

Anthony Rees,

CEO

Tel: +46 46 286 37 80

Email: info@mip.ideon.se

Or visit: http://www.miptechnologies.se